Pair page
Argireline with Vialox
Mechanism-tag overlap and published literature for Argireline and Vialox, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
cosmetic-peptidesnap-25-mimetic
cosmetic-neuromuscular-inhibitor
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Argireline and Vialox have published these mechanism-level observations. Not a co-administration recommendation.
The reference cosmetic neuromuscular peptide. Argireline acts pre-synaptically by mimicking the SNAP-25 N-terminus and disrupting SNARE complex assembly (Blanes-Mira 2002, PMID 18498523; Wang 2013, PMID 23417317), conceptually complementary to Vialox's post-synaptic nAChR antagonism. Combinations covering both pre- and post-synaptic sites are the standard "topical Botox" stack — exemplified by multi-peptide products that include 5–10% Argireline plus 1–3% Vialox plus Syn-Ake.
Quick facts
Argireline
Vialox
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2025 | Argireline | Zdrada-Nowak J, Surgiel-Gemza A, Szatkowska M. Acetyl Hexapeptide-8 in Cosmeceuticals — A Review of Skin Permeability and Efficacy. Int J Mol Sci. 2025 Jun 14;26(12):5722. doi: 10.3390/ijms26125722. PMID: 40565185. (Most recent systematic review; formulation science is the domin… PMID 40565185 | systematic review |
| 2019 | Argireline | Choi SY, Kwon HJ, Ahn GR, Ko EJ, Yoo KH, Kim BJ, Lee C, Kim D. Anti-Wrinkle Efficacy of Cross-Linked Hyaluronic Acid-Based Microneedle Patch with Acetyl Hexapeptide-8 and Epidermal Growth Factor on Korean Skin. Ann Dermatol. 2019 Jun;31(3):263-271. doi: 10.5021/ad.2019.31.3.263.… PMID 33911590 | human trial |
| 2017 | Argireline | Raikou V, Varvaresou A, Panderi I, Papageorgiou E. The efficacy study of the combination of tripeptide-10-citrulline and acetyl hexapeptide-3. A prospective, randomized controlled study. J Cosmet Dermatol. 2017 Jun;16(2):271-278. doi: 10.1111/jocd.12314. PMID: 28150423. (Four-ar… PMID 28150423 | human trial |
| 2013 | Argireline | Wang Y, Wang M, Xiao S, Pan P, Li P, Huo J. The anti-wrinkle efficacy of argireline, a synthetic hexapeptide, in Chinese subjects: a randomized, placebo-controlled study. Am J Clin Dermatol. 2013 Apr;14(2):147-153. doi: 10.1007/s40257-013-0009-9. PMID: 23417317. (The largest ran… PMID 23417317 | human trial |
| 2013 | Argireline | Lungu C, Considine E, Zahir S, Ponsati B, Arrastia S, Hallett M. Pilot study of topical acetyl hexapeptide-8 in the treatment for blepharospasm in patients receiving botulinum toxin therapy. Eur J Neurol. 2013 Mar;20(3):515-518. doi: 10.1111/ene.12009. PMID: 23146065. (NIH / NIN… PMID 23146065 | human trial |
| 2002 | Argireline | Blanes-Mira C, Clemente J, Jodas G, Gil A, Fernández-Ballester G, Ponsati B, Gutierrez L, Pérez-Payá E, Ferrer-Montiel A. A synthetic hexapeptide (Argireline) with antiwrinkle activity. Int J Cosmet Sci. 2002 Oct;24(5):303-310. doi: 10.1046/j.1467-2494.2002.00153.x. PMID: 184985… PMID 18498523 | human pilot |
| 2013 | Argireline | Wang Y, Wang M, Xiao XS, Pan P, Li P, Huo J. The anti wrinkle efficacy of synthetic hexapeptide (Argireline) in Chinese Subjects. J Cosmet Laser Ther. 2013 Aug;15(4):237-241. doi: 10.3109/14764172.2013.769273. PMID: 23607739. (Companion murine / clinical paper — D-galactose-aged… PMID 23607739 | preclinical, in vivo |
| 2015 | Argireline | Kraeling MEK, Zhou W, Wang P, Ogunsola OA. In vitro skin penetration of acetyl hexapeptide-8 from a cosmetic formulation. Cutan Ocul Toxicol. 2015 Mar;34(1):46-52. doi: 10.3109/15569527.2014.894521. PMID: 24754410. (Independent FDA in vitro penetration study — ~0.22% of 10% appl… PMID 24754410 | preclinical, in vitro |
| 2021 | Argireline | Lim SH, Kathuria H, Amir MHB, Zhang X, Duong HTT, Ho PCL, Kang L. High resolution photopolymer for 3D printing of personalised microneedle for transdermal delivery of anti-wrinkle small peptide. J Control Release. 2021 Jan 10;329:907-918. doi: 10.1016/j.jconrel.2020.10.021. PMID… PMID 33068646 | pharmacology |
| 2020 | Argireline | Errante F, Ledwoń P, Latajka R, Rovero P, Papini AM. Cosmeceutical Peptides in the Framework of Sustainable Wellness Economy. Front Chem. 2020 Oct 26;8:572923. doi: 10.3389/fchem.2020.572923. PMID: 33195060. (Contextual review of cosmetic-peptide biochemistry and categorisation;… PMID 33195060 | review |
| 2024 | Argireline | Public Interest in Acetyl Hexapeptide-8: Longitudinal Analysis. JMIR Dermatol. 2024;7:e54217. doi: 10.2196/54217. PMID: 38376906. (Google Trends analysis 2013-2023; post-2022 TikTok-driven consumer search surge; coining of "Botox in a bottle" in popular culture.) PMID 38376906 | research article |
| 2020 | Argireline | Lim SH, Tiew WJ, Zhang J, Ho PC, Kachouie NN, Kang L. Geometrical optimisation of a personalised microneedle eye patch for transdermal delivery of anti-wrinkle small peptide. Biofabrication. 2020;12(3):035003. doi: 10.1088/1758-5090/ab6d37. PMID: 31952064. (3D-printed personalis… PMID 31952064 | research article |
| 1995 | Vialox | Tsai MC, Hsieh WH, Smith LA, Lee CY. Effects of waglerin-I on neuromuscular transmission of mouse nerve-muscle preparations. Toxicon. 1995;33(3):363-371. doi:10.1016/0041-0101(94)00158-5. PMID: 7638875. (Functional characterization of waglerin-I at the muscle-type nAChR — direct… PMID 7638875 | preclinical, in vivo |
| 1992 | Vialox | Aiken SP, Sellin LC, Schmidt JJ, Weinstein SA, McArdle JJ. A novel peptide toxin from Trimeresurus wagleri acts pre- and post-synaptically to block transmission at the rat neuromuscular junction. Pharmacol Toxicol. 1992;70(5 Pt 1):339-343. PMID: 1359525. (Mechanism characterizat… PMID 1359525 | preclinical, in vivo |
| 2017 | Vialox | Tan CH, Tan KY, Yap MK, Tan NH. Venomics of Tropidolaemus wagleri, the sexually dimorphic temple pit viper: Unveiling a deeply conserved atypical toxin arsenal. Sci Rep. 2017;7:43237. doi:10.1038/srep43237. (Modern venomics characterization of the temple pit viper venom containi… | mechanism / discovery |
| 1992 | Vialox | Schmidt JJ, Weinstein SA, Smith LA. Molecular properties and structure-function relationships of lethal peptides from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1992;30(9):1027-1036. doi:10.1016/0041-0101(92)90048-a. PMID: 1440639. (Structure-function characteri… PMID 1440639 | mechanism / discovery |
| 1991 | Vialox | Weinstein SA, Schmidt JJ, Bernheimer AW, Smith LA. Characterization and amino acid sequences of two lethal peptides isolated from venom of Wagler's pit viper, Trimeresurus wagleri. Toxicon. 1991;29(2):227-236. doi:10.1016/0041-0101(91)90107-3. (Original characterization of the w… | mechanism / discovery |
| 2017 | Vialox | Pai VV, Bhandari P, Shukla P. Topical peptides as cosmeceuticals. Indian J Dermatol Venereol Leprol. 2017;83(1):9-18. doi:10.4103/0378-6323.186500. PMID: 27451932. (2017 review of cosmetic peptides including discussion of neurotransmitter inhibitors and curare-mimetic peptides.) PMID 27451932 | review |
| 2017 | Vialox | Schagen SK. Topical Peptide Treatments with Effective Anti-Aging Results. Cosmetics. 2017;4(2):16. doi:10.3390/cosmetics4020016. (MDPI Cosmetics review of the cosmetic-peptide landscape including Pentapeptide-3 / Vialox; not PubMed-indexed but widely cited.) | review |
| 2018 | Vialox | DSM Personal Care / Pentapharm. Pentapeptide-3 (Vialox PT) — Product Brochure. Basel, Switzerland: DSM; 2018 (and subsequent revisions). (Manufacturer brochure documenting Pentapharm in-house clinical evaluation methodology; the underlying source of the "49% wrinkle reduction" h… | industry documentation |
| 2017 | Vialox | Centerchem Inc. Vialox® Pentapeptide-3 — Technical Data Sheet. Norwalk, CT: Centerchem; 2017 (and subsequent technical bulletins). (Primary manufacturer technical literature describing in-vitro and in-vivo claims; cited here as the documented source of widely repeated wrinkle-re… | industry documentation |
| 2015 | Vialox | Pickart L, Vasquez-Soltero JM, Margolina A. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration. Biomed Res Int. 2015;2015:648108. doi:10.1155/2015/648108. PMID: 26050778. (Reference for the major cosmetic carrier peptide commonly stacked with V… PMID 26050778 | research article |
| 2010 | Vialox | Reszko AE, Berson D, Lupo MP. Cosmeceuticals: practical applications. Obstet Gynecol Clin North Am. 2010;37(4):547-569,viii. doi:10.1016/j.ogc.2010.09.006. PMID: 21093749. (Practical clinical-dermatology overview of cosmeceutical peptide categories with reference to Vialox-class… PMID 21093749 | research article |
| 2007 | Vialox | Lupo MP, Cole AL. Cosmeceutical peptides. Dermatol Ther. 2007;20(5):343-349. doi:10.1111/j.1529-8019.2007.00148.x. PMID: 18045359. (Widely cited dermatology review that catalogues Pentapeptide-3 / Vialox alongside Argireline as neurotransmitter-affecting cosmetic peptides.) PMID 18045359 | research article |
Related pair pages
More research context
Frequently asked
Have Argireline and Vialox been studied together?
Researchers have published mechanistic-level co-administration discussion of Argireline and Vialox. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Argireline and Vialox share?
Argireline and Vialox do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of Argireline and Vialox?
Argireline: Cosmetic ingredient (not a drug). Vialox: Cosmetic ingredient (not a drug). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Argireline and Vialox?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Argireline profile and the Vialox profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026